Amgen Inc (AMGN): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 1.1%. By the end of trading, Amgen fell $5.98 (-5.0%) to $113.32 on heavy volume. Throughout the day, 10,910,869 shares of Amgen exchanged hands as compared to its average daily volume of 3,719,900 shares. The stock ranged in price between $111.51-$116.45 after having opened the day at $116.06 as compared to the previous trading day's close of $119.30. Other companies within the Health Care sector that declined today were: Intuitive Surgical ( ISRG), down 11.5%, XenoPort ( XNPT), down 10.0%, PTC Therapeutics ( PTCT), down 9.3% and Immunomedics ( IMMU), down 9.2%.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $88.5 billion and is part of the drugs industry. Shares are up 4.6% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, Recro Pharma ( REPH), up 24.4%, Aoxing Pharmaceutical ( AXN), up 14.3%, GW Pharmaceuticals ( GWPH), up 13.9% and XTL Biopharmaceuticals ( XTLB), up 12.9% , were all gainers within the health care sector with Illumina ( ILMN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback